Guj. Themis Bio. Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Current sales closely match production; capacity utilization is above 100% due to prior inventory.
- Strong demand outlook for the rest of FY24; aiming to maintain or improve capacity utilization from last year's 75-80%.
- Expected revenue growth tied to full capacity utilization and new API block commissioning from December 2023.
- New API plant focusing on Rifapentine with flexible multi-purpose production capacity (~7 tons/month).
- Anticipate significant revenue increase once API revenues start, but exact growth magnitude is uncertain.
- Earlier guided 25-30% revenue growth in FY24 if 100% capacity utilization is sustained.
- Inventory normalized; no immediate benefit from inventory build-up expected going forward.
- Long-term growth boosted by expanding fermentation-based product portfolio and new CAPEX plans, which may exceed Rs. 200 crores.
- Market shifts like Rifapentine adoption and rifaximin patent expiry could positively impact volumes.
See what Guj. Themis Bio. management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Gujarat Themis Biosyn Limited is planning significant CAPEX over the next three years, likely increasing beyond the initially planned Rs. 200 crores.
- Funding for this CAPEX will be partially through internal accruals.
- The company will also pursue debt-equity financing but has not finalized the exact mix of debt or equity.
- A decision on the mode of funding (debt, equity, or mix) is expected within the next six to nine months.
- No specific mention of immediate fundraising via equity dilution; evaluations are ongoing.
See what Guj. Themis Bio. management said on order book — free account, 30 seconds.
Capex plans
Yes- Phase-I CAPEX of around Rs. 80 crores is near completion with some additional minor spend expected until plant commissioning in December 2023.
- Construction of new API block and R&D block to be commissioned by December 2023.
- Additional fermentation capacity expansion underway, expected ready by 2025.
- Total CAPEX planned over three years initially estimated at Rs. 200 crores but now expected to be at least double that amount, possibly more.
- Funding will be through a mix of internal accruals and debt-equity options under consideration over the next 6-9 months.
- The company is applying for incentives from the Gujarat Government Biotechnology Promotion Board but not participating in the central government's PLI scheme.
- New facilities will comply with global regulatory norms targeting both domestic and export markets.
Track Guj. Themis Bio. — get its next earnings analysis in your feed
Margin guidance
Category 3- The company anticipates strong demand and expects better capacity utilization this year compared to the previous 75%-80% last year.
- Revenues for FY24 are expected to grow if 100% capacity utilization is achieved, targeting around Rs.190-200 crores.
- Growth is linked to selling what is produced, with no backlog inventory, implying stable real-time sales.
- API block commissioning by December 2023 is expected to generate incremental revenues starting FY25.
- Rifapentine production presents significant growth potential with promising pricing and market demand.
- EBITDA margins were impacted due to increased R&D and skilled workforce investments.
- EPS for Q2 FY24 was reported at Rs.8.63 per share; half-year EPS stands at Rs.20.83.
- CAPEX associated with growth is expected to increase (possibly doubling from Rs.200 crores), funded by internal accruals and debt-equity mix.
- R&D expenses may fluctuate, reflecting developmental activity levels.
Order book
- The transcript does not explicitly mention the exact current or expected order book or pending orders in numerical terms.
- Dr. Sachin Patel indicated strong demand currently with no backlog of inventory, implying orders are being fulfilled as produced.
- For Rifapentine, initial Indian government tenders indicate demand around 30-40 MT annually, possibly higher.
- The company anticipates growth if 100% capacity utilization is maintained, targeting Rs.190-200 crores top-line for FY24.
- Production matches sales currently; no carryover inventory suggests orders are being met promptly.
- New API capacity commissioning expected by December 2023 aims to support future order fulfillment and revenue growth.
- Demand for their products, including emerging ones like Rifapentine, is described as strong and solid for the near term.
How does Guj. Themis Bio. rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Guj. Themis Bio. rank in Pharmaceuticals & Biotechnology?
Compare Guj. Themis Bio. against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Guj. Themis Bio.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma Science Ltd (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…